Bristol-Myers' checkpoint combo scores in PhIII study; AstraZeneca hands Circassia positive data for COPD drug; Woodford apologizes again
⇨ Bristol-Myers Squibb did get some good news on the checkpoint front today. The company says that their combination of Opdivo and Yervoy scored good results for overall survival in advanced renal cell carcinoma in their CheckMate -214 study, comparing their combo to sunitinib. Analysts say the good results for two established drugs is likely to trigger a quick OK from regulators.
⇨ The UK’s Circassia got a new lease on life after the collapse of its failed allergy meds when it licensed Duaklir and Tudorza from AstraZeneca. And now the pharma giant is handing over positive results from a COPD study that the biotech believes will open the door to a valuable US market.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.